Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings
Arcutis Biotherapeutics shares slid 5.3% to $28.29 in afternoon trading on Friday, after climbing as high as $30.70 earlier. The stock was last at the session low.

Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading.